1443017-56-8

Basic information

• Product Name: C₂₂H₁₉BrFNO₄
• Synonyms: C₂₂H₁₉BrFNO₄
• CAS NO: 1443017-56-8
• Molecular Weight: 460.3
• Mol File: 1443017-56-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₂H₁₉BrFNO₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₂H₁₉BrFNO₄(1443017-56-8)
• EPA Substance Registry System: C₂₂H₁₉BrFNO₄(1443017-56-8)

Safety Data

• Hazardous Substances Data: 1443017-56-8(Hazardous Substances Data)

Upstream product

• 1443017-79-5 C₇H₃BrFNO 
• 66726-11-2 (3αS,5αS,9βS)-5α,9-dimethyl-3-methylene-3α,5,5α,9β-tetrahydronaphtho[1,2-β]furan-2,8(3H,4H)-dione 

Relevant articles and documents

Synthesis and anticancer activity of novel spiro-isoxazoline and spiro-isoxazolidine derivatives of α-santonin

In the present study, novel spiro derivatives of α-santonin were prepared and tested for their anticancer activity against a panel of six human cancer cell lines. Spiro-isoxazoline and spiro-isoxazolidine derivatives have been generated on C-ring of α-santonin (α-methylene-γ- butyrolactone) by the 1,3-dipolar cycloaddition of α-santonin derivative 6 with nitrile oxides 7 and nitrones 9 respectively. Among all, compound 10b″ had shown IC50 of 0.01, 0.5 and 0.3 μM against PC-3, THP-1 and MCF-7 cell lines respectively. Further, flow cytometry studies showed that PC-3 cells treated with the spiro-isoxazolidine derivative 10b″ were arrested in the sub G1 phase of the cell cycle in a concentration dependent manner. The spiro-isoxazolidine derivative 10b″ also showed concentration dependent inhibitory activity against NF-κB, p65 with 57% inhibition in 24 h at 10 μM.